An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation

Basit Öğe Kaydı
dc.authoridErtan Yetkin / 0000-0001-8862-750X
dc.authorscopusidErtan Yetkin / 7004009443
dc.authorwosidErtan Yetkin / AGX-3712-2022
dc.contributor.authorYetkin, Ertan
dc.contributor.authorYalta, K.
dc.contributor.authorWaltenberger, J.
dc.date.accessioned2020-08-30T20:06:07Z
dc.date.available2020-08-30T20:06:07Z
dc.date.issued2020
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractDerivatives of quinolone, namely quinidine, quinine and hydroxychloroquine (HCQ, hydroxylated form of aminoquinone), have been used for decades in the treatment of different diseases, including malaria, rheumatological diseases, cardiac arrhythmias and, most recently, the new coronavirus disease 2019 (COVID-19). Although quinidine is no longer widely used for the termination and prevention of arrhythmias, quinine and HCQ are still in common use for rheumatological diseases and malaria. Their common side-effects, QT prolongation and a risk of proarrhythmia, have re-emerged as a result of the widespread use of HCQ in the treatment of COVID-19. In fact, they all show the main electrophysiological aspects of class Ia antiarrhythmic drugs. This antiarrhythmic effect is mainly characterised by the inhibition of fast Na channels and to a lesser extent by K-channel inhibition. However, this class I antiarrhythmic effect is accompanied by a proarrhythmic effect by prolonging the QT interval, thereby facilitating the occurrence of torsades de pointes or ventricular arrhythmias. Therefore, being a derivative of quinolone, like quinidine, and manifesting class Ia antiarrhythmic drug effects, HCQ has been given all the attention regarding theen_US
dc.identifier.citationYetkin, E., Yalta, K., & Waltenberger, J. (2020). An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation. NETHERLANDS HEART JOURNAL, 28(7–8), 437–438. https://doi.org/10.1007/s12471-020-01464-4en_US
dc.identifier.doi10.1007/s12471-020-01464-4en_US
dc.identifier.endpage438en_US
dc.identifier.issn1568-5888en_US
dc.identifier.issn1876-6250en_US
dc.identifier.pmid32643072en_US
dc.identifier.scopus2-s2.0-85087676430en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage437en_US
dc.identifier.urihttps://doi.org/10.1007/s12471-020-01464-4
dc.identifier.urihttps://hdl.handle.net/20.500.12713/373
dc.identifier.volume28en_US
dc.identifier.wosWOS:000546549300001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorYetkin, Ertanen_US
dc.language.isoenen_US
dc.publisherBohn Stafleu Van Loghum Bven_US
dc.relation.ispartofNetherlands Heart Journalen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleAn antiarrhythmic approach to hydroxychloroquine-induced QT prolongationen_US
dc.typeLetteren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
h164.pdf
Boyut:
146.45 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu